Portfolio Holdings Detail for ISIN IE00BDZVHG35
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 77
Stock Name / Fund iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer Blackrock

ETF Ticker BTEE(USD) LSE
ETF Ticker BTEE.L(GBP) LSE

Holdings detail for INVA

Stock Name	Innoviva Inc
Ticker	INVA(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US45781M1018
LEI	549300ACOX4QTBES6535

Show aggregate INVA holdings

News associated with INVA

Innoviva (NASDAQ:INVA) Stock Rating Upgraded by Wall Street Zen: Wall Street Zen upgraded shares of Innoviva (NASDAQ:INVA – Free Report) from a buy rating to a strong-buy rating in a report released on Monday morning. Several other analysts also recently weighed in on INVA. Cantor Fitzgerald began coverage on Innoviva in a research report on Friday, July 11th. They issued an “overweight” rating and […] - 2025-09-02 03:06:54
Comparing Innoviva (NASDAQ:INVA) and Novo Nordisk A/S (NYSE:NVO): Innoviva (NASDAQ:INVA – Get Free Report) and Novo Nordisk A/S (NYSE:NVO – Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings. Institutional & Insider Ownership 99.1% of Innoviva shares […] - 2025-09-01 03:01:00
Deutsche Bank AG Trims Stock Position in Innoviva, Inc. (NASDAQ:INVA): Deutsche Bank AG decreased its position in shares of Innoviva, Inc. (NASDAQ:INVA – Free Report) by 4.2% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 827,730 shares of the biotechnology company’s stock after selling 36,549 shares during the quarter. Deutsche Bank AG owned approximately […] - 2025-08-15 05:51:00
Innoviva (NASDAQ:INVA) and AbbVie (NYSE:ABBV) Financial Comparison: Innoviva (NASDAQ:INVA – Get Free Report) and AbbVie (NYSE:ABBV – Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership. Profitability This table compares Innoviva and AbbVie’s net margins, return […] - 2025-08-13 04:40:48
Innoviva (NASDAQ:INVA) Stock Price Up 8.2% on Analyst Upgrade: Innoviva, Inc. (NASDAQ:INVA – Get Free Report) shares were up 8.2% on Monday after HC Wainwright raised their price target on the stock from $40.00 to $45.00. HC Wainwright currently has a buy rating on the stock. Innoviva traded as high as $19.66 and last traded at $19.84. Approximately 205,104 shares traded hands during trading, […] - 2025-08-13 02:55:07
Innoviva (NASDAQ:INVA) and AbbVie (NYSE:ABBV) Head-To-Head Review: Innoviva (NASDAQ:INVA – Get Free Report) and AbbVie (NYSE:ABBV – Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations. Earnings & Valuation This table compares Innoviva and AbbVie”s gross […] - 2025-08-06 04:40:51
Principal Financial Group Inc. Grows Stock Position in Innoviva, Inc. (NASDAQ:INVA): Principal Financial Group Inc. boosted its stake in Innoviva, Inc. (NASDAQ:INVA – Free Report) by 2.6% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 305,476 shares of the biotechnology company’s stock after acquiring an additional 7,700 shares during the quarter. […] - 2025-07-17 05:51:13
Innoviva (NASDAQ:INVA) vs. Merck & Co., Inc. (NYSE:MRK) Head to Head Comparison: Innoviva (NASDAQ:INVA – Get Free Report) and Merck & Co., Inc. (NYSE:MRK – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, earnings, dividends and institutional ownership. Earnings & Valuation This table compares Innoviva […] - 2025-07-17 04:38:50
New York State Teachers Retirement System Has $1.04 Million Holdings in Innoviva, Inc. (NASDAQ:INVA): New York State Teachers Retirement System lessened its holdings in shares of Innoviva, Inc. (NASDAQ:INVA – Free Report) by 5.7% during the first quarter, Holdings Channel.com reports. The institutional investor owned 57,498 shares of the biotechnology company’s stock after selling 3,448 shares during the quarter. New York State Teachers Retirement System’s holdings in Innoviva were […] - 2025-07-10 04:59:01
Illinois Municipal Retirement Fund Reduces Stock Position in Innoviva, Inc. (NASDAQ:INVA): Illinois Municipal Retirement Fund lowered its stake in Innoviva, Inc. (NASDAQ:INVA – Free Report) by 4.3% during the 1st quarter, HoldingsChannel reports. The firm owned 27,806 shares of the biotechnology company’s stock after selling 1,260 shares during the period. Illinois Municipal Retirement Fund’s holdings in Innoviva were worth $504,000 as of its most recent filing […] - 2025-07-04 04:46:49
Exchange Traded Concepts LLC Grows Stock Holdings in Innoviva, Inc. (NASDAQ:INVA): Exchange Traded Concepts LLC grew its holdings in Innoviva, Inc. (NASDAQ:INVA – Free Report) by 8.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 176,025 shares of the biotechnology company’s stock after purchasing an additional 14,020 shares during the quarter. Exchange […] - 2025-06-17 06:15:01
FDA Grants Priority Review For Innoviva's Zoliflodacin For Treatment Of Uncomplicated Gonorrhea: (RTTNews) - Innoviva Specialty Therapeutics, Inc., a unit of Innoviva, Inc. (INVA), in partnership with the Global Antibiotic Research & Development Partnership (GARDP), Thursday said that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the New Drug Ap - 2025-06-12 08:48:08
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Buys 1,162 Shares of Innoviva, Inc. (NASDAQ:INVA): MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Innoviva, Inc. (NASDAQ:INVA – Free Report) by 3.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 31,490 shares of the biotechnology company’s stock after acquiring an additional 1,162 shares […] - 2025-05-29 05:40:50
Two Sigma Investments LP Has $4.56 Million Stock Position in Innoviva, Inc. (NASDAQ:INVA): Two Sigma Investments LP reduced its position in shares of Innoviva, Inc. (NASDAQ:INVA – Free Report) by 45.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 262,739 shares of the biotechnology company’s stock after selling 221,073 shares […] - 2025-05-28 05:20:52
10,612 Shares in Innoviva, Inc. (NASDAQ:INVA) Purchased by Cubist Systematic Strategies LLC: Cubist Systematic Strategies LLC purchased a new position in Innoviva, Inc. (NASDAQ:INVA – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 10,612 shares of the biotechnology company’s stock, valued at approximately $184,000. Other hedge funds and other institutional investors also […] - 2025-05-19 04:38:50
Sum Up The Parts: IJR Could Be Worth $128: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-05-15 07:40:06
MetLife Investment Management LLC Acquires 1,731 Shares of Innoviva, Inc. (NASDAQ:INVA): MetLife Investment Management LLC raised its holdings in shares of Innoviva, Inc. (NASDAQ:INVA – Free Report) by 5.2% in the 4th quarter, Holdings Channel reports. The firm owned 34,961 shares of the biotechnology company’s stock after purchasing an additional 1,731 shares during the quarter. MetLife Investment Management LLC’s holdings in Innoviva were worth $607,000 at […] - 2025-05-05 05:30:51
Innoviva (NASDAQ:INVA) Upgraded by StockNews.com to “Buy” Rating: Innoviva (NASDAQ:INVA – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued to investors on Wednesday. Separately, Scotiabank started coverage on shares of Innoviva in a report on Friday, March 7th. They issued a “sector outperform” rating and a $55.00 […] - 2025-05-02 02:46:47
Dimensional Fund Advisors LP Grows Position in Innoviva, Inc. (NASDAQ:INVA): Dimensional Fund Advisors LP raised its position in Innoviva, Inc. (NASDAQ:INVA – Free Report) by 4.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,919,518 shares of the biotechnology company’s stock after buying an additional 226,592 shares during the […] - 2025-04-30 06:00:57
Look Under The Hood: IJR Has 39% Upside: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-04-14 09:05:39
Innoviva (NASDAQ:INVA) Downgraded to “Hold” Rating by StockNews.com: Innoviva (NASDAQ:INVA – Get Free Report) was downgraded by research analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued on Tuesday. Separately, Scotiabank started coverage on shares of Innoviva in a research report on Friday, March 7th. They set a “sector outperform” rating and a $55.00 target price […] - 2025-04-03 02:27:03
72,400 Shares in Innoviva, Inc. (NASDAQ:INVA) Acquired by KLP Kapitalforvaltning AS: KLP Kapitalforvaltning AS acquired a new stake in shares of Innoviva, Inc. (NASDAQ:INVA – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 72,400 shares of the biotechnology company’s stock, valued at approximately $1,256,000. KLP Kapitalforvaltning AS owned 0.12% of Innoviva as […] - 2025-03-30 06:16:54
Innoviva (NASDAQ:INVA) Upgraded by StockNews.com to “Buy” Rating: StockNews.com upgraded shares of Innoviva (NASDAQ:INVA – Free Report) from a hold rating to a buy rating in a research note published on Monday morning. Separately, Scotiabank began coverage on Innoviva in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $55.00 target price on the stock. Read Our […] - 2025-03-25 04:09:01
Innoviva (NASDAQ:INVA) Upgraded at StockNews.com: StockNews.com upgraded shares of Innoviva (NASDAQ:INVA – Free Report) from a hold rating to a buy rating in a report released on Friday. Separately, Scotiabank started coverage on Innoviva in a research report on Friday. They set a “sector outperform” rating and a $55.00 price objective on the stock. Check Out Our Latest Analysis on […] - 2025-03-10 04:28:55
Scotiabank Begins Coverage on Innoviva (NASDAQ:INVA): Scotiabank began coverage on shares of Innoviva (NASDAQ:INVA – Free Report) in a research report released on Friday morning, MarketBeat Ratings reports. The brokerage issued a sector outperform rating and a $55.00 target price on the biotechnology company’s stock. Separately, StockNews.com cut Innoviva from a “buy” rating to a “hold” rating in a research report […] - 2025-03-10 04:28:54
Illinois Municipal Retirement Fund Increases Holdings in Innoviva, Inc. (NASDAQ:INVA): Illinois Municipal Retirement Fund increased its stake in Innoviva, Inc. (NASDAQ:INVA – Free Report) by 2.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 29,066 shares of the biotechnology company’s stock after acquiring an additional 784 shares during […] - 2025-03-05 08:41:50

iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) INVA holdings

Date	Number of INVA Shares Held	Base Market Value of INVA Shares	Local Market Value of INVA Shares	Change in INVA Shares Held	Change in INVA Base Value	Current Price per INVA Share Held	Previous Price per INVA Share Held
2025-11-11 (Tuesday)	40,231	USD 881,059	USD 881,059	0	USD 41,438	USD 21.9	USD 20.87
2025-11-10 (Monday)	40,231	USD 839,621	USD 839,621	103	USD 2,551	USD 20.87	USD 20.86
2025-11-07 (Friday)	40,128	USD 837,070	USD 837,070	0	USD 11,236	USD 20.86	USD 20.58
2025-11-06 (Thursday)	40,128	USD 825,834	USD 825,834	103	USD 96,178	USD 20.58	USD 18.23
2025-11-05 (Wednesday)	40,025	USD 729,656	USD 729,656	0	USD 3,202	USD 18.23	USD 18.15
2025-11-04 (Tuesday)	40,025	USD 726,454	USD 726,454	104	USD 3,485	USD 18.15	USD 18.11
2025-11-03 (Monday)	39,921	USD 722,969	USD 722,969	0	USD -3,593	USD 18.11	USD 18.2
2025-10-31 (Friday)	39,921	USD 726,562	USD 726,562	0	USD 9,980	USD 18.2	USD 17.95
2025-10-30 (Thursday)	39,921	USD 716,582	USD 716,582	520	USD 24,306	USD 17.95	USD 17.57
2025-10-29 (Wednesday)	39,401	USD 692,276	USD 692,276	208	USD -1,048	USD 17.57	USD 17.69
2025-10-28 (Tuesday)	39,193	USD 693,324	USD 693,324	0	USD -1,176	USD 17.69	USD 17.72
2025-10-27 (Monday)	39,193	USD 694,500	USD 694,500	0	USD 392	USD 17.72	USD 17.71

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of INVA by Blackrock for IE00BDZVHG35

Show aggregate share trades of INVA

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-11-10 BUY 103 20.920 20.255 20.321 USD 2,093 18.80
2025-11-06 BUY 103 20.900 18.850 19.055 USD 1,963 18.78
2025-11-04 BUY 104 18.300 17.910 17.949 USD 1,867 18.78
2025-10-30 BUY 520 17.950 17.530 17.572 USD 9,137 18.80
2025-10-29 BUY 208 17.570 17.800 17.777 USD 3,698 18.80
2025-10-22 SELL -412 18.350 18.790 18.746 USD -7,723 18.83 Profit of 34 on sale
2025-10-20 BUY 206 17.210 17.330 17.318 USD 3,568 18.85
2025-10-17 BUY 515 17.270 17.500 17.477 USD 9,001 18.85
2025-10-15 BUY 824 17.390 17.480 17.471 USD 14,396 18.86
2025-10-03 BUY 728 17.480 17.790 17.759 USD 12,929 18.88
2025-10-02 BUY 104 17.660 18.090 18.047 USD 1,877 18.89
2025-09-30 BUY 208 18.250 18.580 18.547 USD 3,858 18.90
2025-09-26 BUY 208 18.860 18.880 18.878 USD 3,927 18.90
2025-09-25 BUY 208 18.570 19.370 19.290 USD 4,012 18.90
2025-09-18 BUY 109 19.890 19.900 19.899 USD 2,169 18.90
2025-09-17 BUY 327 19.380 19.660 19.632 USD 6,420 18.89
2025-07-17 SELL -216 19.880 20.580 20.510 USD -4,430 18.88 Loss of -353 on sale
2025-07-11 SELL -864 18.770 19.400 19.337 USD -16,707 18.86 Loss of -416 on sale
2025-07-02 BUY 5,940 19.400 19.870 19.823 USD 117,749 18.85
2025-06-25 BUY 216 20.480 20.840 20.804 USD 4,494 18.81
2025-06-20 BUY 1,436 21.000 21.590 21.531 USD 30,919 18.76
2025-06-11 BUY 206 21.370 21.730 21.694 USD 4,469 18.62
2025-06-10 BUY 206 21.530 21.980 21.935 USD 4,519 18.60
2025-06-04 SELL -104 20.880 20.960 20.952 USD -2,179 18.51 Loss of -254 on sale
2025-04-23 BUY 103 18.370 18.620 18.595 USD 1,915 18.42
2025-04-10 SELL -824 17.100 17.260 17.244 USD -14,209 18.46 Profit of 1,004 on sale
2025-04-08 SELL -103 17.250 17.890 17.826 USD -1,836 18.49 Profit of 68 on sale
2025-04-07 SELL -103 17.510 17.840 17.807 USD -1,834 18.50 Profit of 71 on sale
2025-04-04 SELL -520 17.720 18.030 17.999 USD -9,359 18.51 Profit of 266 on sale
2025-04-01 BUY 428 17.940 18.140 18.120 USD 7,755 18.52
2025-03-31 SELL -312 18.130 18.270 18.256 USD -5,696 18.53 Profit of 84 on sale
2025-03-21 BUY 1,399 17.270 17.400 17.387 USD 24,324 18.60
2025-03-14 SELL -1,600 17.390 17.520 17.507 USD -28,011 18.69 Profit of 1,893 on sale
2025-03-07 SELL -200 17.640 17.850 17.829 USD -3,566 18.78 Profit of 190 on sale
2025-03-04 SELL -100 17.570 18.190 18.128 USD -1,813 18.84 Profit of 71 on sale
2025-02-25 BUY 200 18.030 18.260 18.237 USD 3,647 18.92
2025-02-19 SELL -99 18.030 18.200 18.183 USD -1,800 18.99 Profit of 80 on sale
2025-02-13 BUY 297 18.220 18.330 18.319 USD 5,441 19.06
2025-02-12 BUY 99 17.980 18.050 18.043 USD 1,786 19.08
2025-02-11 BUY 396 18.060 18.080 18.078 USD 7,159 19.10
2024-12-30 SELL -3,928 17.380 17.530 17.515 USD -68,799 19.42 Profit of 7,465 on sale
2024-11-18 SELL -1,638 18.950 19.190 19.166 USD -31,394 19.80 Profit of 1,035 on sale
2024-11-08 SELL -109 20.180 20.320 20.306 USD -2,213 19.73 Loss of -62 on sale
2024-10-21 SELL -110 19.850 20.020 20.003 USD -2,200 0.00 Loss of -2,200 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-11-10	BUY	103	20.920	20.255	20.321	USD 2,093	18.80
2025-11-06	BUY	103	20.900	18.850	19.055	USD 1,963	18.78
2025-11-04	BUY	104	18.300	17.910	17.949	USD 1,867	18.78
2025-10-30	BUY	520	17.950	17.530	17.572	USD 9,137	18.80
2025-10-29	BUY	208	17.570	17.800	17.777	USD 3,698	18.80
2025-10-22	SELL	-412	18.350	18.790	18.746	USD -7,723	18.83 Profit of 34 on sale
2025-10-20	BUY	206	17.210	17.330	17.318	USD 3,568	18.85
2025-10-17	BUY	515	17.270	17.500	17.477	USD 9,001	18.85
2025-10-15	BUY	824	17.390	17.480	17.471	USD 14,396	18.86
2025-10-03	BUY	728	17.480	17.790	17.759	USD 12,929	18.88
2025-10-02	BUY	104	17.660	18.090	18.047	USD 1,877	18.89
2025-09-30	BUY	208	18.250	18.580	18.547	USD 3,858	18.90
2025-09-26	BUY	208	18.860	18.880	18.878	USD 3,927	18.90
2025-09-25	BUY	208	18.570	19.370	19.290	USD 4,012	18.90
2025-09-18	BUY	109	19.890	19.900	19.899	USD 2,169	18.90
2025-09-17	BUY	327	19.380	19.660	19.632	USD 6,420	18.89
2025-07-17	SELL	-216	19.880	20.580	20.510	USD -4,430	18.88 Loss of -353 on sale
2025-07-11	SELL	-864	18.770	19.400	19.337	USD -16,707	18.86 Loss of -416 on sale
2025-07-02	BUY	5,940	19.400	19.870	19.823	USD 117,749	18.85
2025-06-25	BUY	216	20.480	20.840	20.804	USD 4,494	18.81
2025-06-20	BUY	1,436	21.000	21.590	21.531	USD 30,919	18.76
2025-06-11	BUY	206	21.370	21.730	21.694	USD 4,469	18.62
2025-06-10	BUY	206	21.530	21.980	21.935	USD 4,519	18.60
2025-06-04	SELL	-104	20.880	20.960	20.952	USD -2,179	18.51 Loss of -254 on sale
2025-04-23	BUY	103	18.370	18.620	18.595	USD 1,915	18.42
2025-04-10	SELL	-824	17.100	17.260	17.244	USD -14,209	18.46 Profit of 1,004 on sale
2025-04-08	SELL	-103	17.250	17.890	17.826	USD -1,836	18.49 Profit of 68 on sale
2025-04-07	SELL	-103	17.510	17.840	17.807	USD -1,834	18.50 Profit of 71 on sale
2025-04-04	SELL	-520	17.720	18.030	17.999	USD -9,359	18.51 Profit of 266 on sale
2025-04-01	BUY	428	17.940	18.140	18.120	USD 7,755	18.52
2025-03-31	SELL	-312	18.130	18.270	18.256	USD -5,696	18.53 Profit of 84 on sale
2025-03-21	BUY	1,399	17.270	17.400	17.387	USD 24,324	18.60
2025-03-14	SELL	-1,600	17.390	17.520	17.507	USD -28,011	18.69 Profit of 1,893 on sale
2025-03-07	SELL	-200	17.640	17.850	17.829	USD -3,566	18.78 Profit of 190 on sale
2025-03-04	SELL	-100	17.570	18.190	18.128	USD -1,813	18.84 Profit of 71 on sale
2025-02-25	BUY	200	18.030	18.260	18.237	USD 3,647	18.92
2025-02-19	SELL	-99	18.030	18.200	18.183	USD -1,800	18.99 Profit of 80 on sale
2025-02-13	BUY	297	18.220	18.330	18.319	USD 5,441	19.06
2025-02-12	BUY	99	17.980	18.050	18.043	USD 1,786	19.08
2025-02-11	BUY	396	18.060	18.080	18.078	USD 7,159	19.10
2024-12-30	SELL	-3,928	17.380	17.530	17.515	USD -68,799	19.42 Profit of 7,465 on sale
2024-11-18	SELL	-1,638	18.950	19.190	19.166	USD -31,394	19.80 Profit of 1,035 on sale
2024-11-08	SELL	-109	20.180	20.320	20.306	USD -2,213	19.73 Loss of -62 on sale
2024-10-21	SELL	-110	19.850	20.020	20.003	USD -2,200	0.00 Loss of -2,200 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of INVA

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	65,930	0	149,254	44.2%
2025-09-18	54,680	0	119,648	45.7%
2025-09-17	40,834	0	95,181	42.9%
2025-09-16	227,908	28,600	465,820	48.9%
2025-09-15	85,010	0	176,819	48.1%
2025-09-12	156,615	104,900	229,858	68.1%
2025-09-11	146,754	0	312,186	47.0%
2025-09-10	75,303	0	156,342	48.2%
2025-09-09	94,428	5,671	191,257	49.4%
2025-09-08	77,521	0	154,072	50.3%
2025-09-05	88,670	0	245,183	36.2%
2025-09-04	86,526	0	170,267	50.8%
2025-09-03	48,464	194	153,630	31.5%
2025-09-02	119,972	0	249,504	48.1%
2025-08-29	91,265	0	190,465	47.9%
2025-08-28	48,895	0	140,299	34.9%
2025-08-27	107,253	32,800	194,107	55.3%
2025-08-26	23,532	0	145,160	16.2%
2025-08-25	51,167	0	168,306	30.4%
2025-08-22	35,425	0	126,656	28.0%
2025-08-21	25,225	200	118,578	21.3%
2025-08-20	23,281	590	143,018	16.3%
2025-08-19	16,731	0	109,949	15.2%
2025-08-18	190,992	0	438,041	43.6%
2025-08-15	62,276	0	302,389	20.6%
2025-08-14	56,515	0	301,294	18.8%
2025-08-13	126,567	39	384,530	32.9%
2025-08-12	221,544	187	351,909	63.0%
2025-08-11	368,099	0	589,100	62.5%
2025-08-08	108,860	0	228,597	47.6%
2025-08-07	220,464	600	484,319	45.5%
2025-08-06	65,725	2	279,150	23.5%
2025-08-05	42,131	0	166,651	25.3%
2025-08-04	51,724	14	196,347	26.3%
2025-08-01	150,400	0	358,924	41.9%
2025-07-31	48,482	0	193,499	25.1%
2025-07-30	27,118	0	151,617	17.9%
2025-07-29	29,865	0	121,240	24.6%
2025-07-28	121,974	0	302,769	40.3%
2025-07-25	130,850	0	367,274	35.6%
2025-07-24	30,190	1	218,543	13.8%
2025-07-23	43,352	0	213,256	20.3%
2025-07-22	22,737	789	211,775	10.7%
2025-07-21	34,627	0	151,496	22.9%
2025-07-18	42,859	0	211,821	20.2%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer	Blackrock
ETF Ticker	BTEE(USD) LSE
ETF Ticker	BTEE.L(GBP) LSE